DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watanabe, Y.
Right arrow Articles by Yokoi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, Y.
Right arrow Articles by Yokoi, T.

Vol. 30, Issue 12, 1462-1469, December 2002

Troglitazone Glucuronidation in Human Liver and Intestine Microsomes: High Catalytic Activity of UGT1A8 and UGT1A10

Yuichiro Watanabe, Miki Nakajima, and Tsuyoshi Yokoi

Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan

Troglitazone glucuronidation in human liver and intestine microsomes and recombinant UDP-glucuronosyltransferases (UGTs) were thoroughly characterized. All recombinant UGT isoforms in baculovirus-infected insect cells (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) exhibited troglitazone glucuronosyltransferase activity. Especially UGT1A8 and UGT1A10, which are expressed in extrahepatic tissues such as stomach, intestine, and colon, showed high catalytic activity, followed by UGT1A1 and UGT1A9. The kinetics of the troglitazone glucuronidation in the recombinant UGT1A10 and UGT1A1 exhibited an atypical pattern of substrate inhibition when the substrate concentration was over 200 µM. With a Michaelis-Menten equation at 6 to 200 µM troglitazone, the Km value was 11.1 ± 5.8 µM and the Vmax value was 33.6 ± 3.7 pmol/min/mg protein in recombinant UGT1A10. In recombinant UGT1A1, the Km value was 58.3 ± 29.2 µM and the Vmax value was 12.3 ± 2.5 pmol/min/mg protein. The kinetics of the troglitazone glucuronidation in human liver and jejunum microsomes also exhibited an atypical pattern. The Km value was 13.5 ± 2.0 µM and the Vmax value was 34.8 ± 1.2 pmol/min/mg for troglitazone glucuronidation in human liver microsomes, and the Km value was 8.1 ± 0.3 µM and the Vmax was 700.9 ± 4.3 pmol/min/mg protein in human jejunum microsomes. When the intrinsic clearance was estimated with the in vitro kinetic parameter, microsomal protein content, and weight of tissue, troglitazone glucuronidation in human intestine was 3-fold higher than that in human livers. Interindividual differences in the troglitazone glucuronosyltransferase activity in liver microsomes from 13 humans were at most 2.2-fold. The troglitazone glucuronosyltransferase activity was significantly (r = 0.579, p < 0.05) correlated with the beta -estradiol 3-glucuronosyltransferase activity, which is mainly catalyzed by UGT1A1. The troglitazone glucuronosyltransferase activity in pooled human liver microsomes was strongly inhibited by bilirubin (IC50 = 1.9 µM), a typical substrate of UGT1A1. These results suggested that the troglitazone glucuronidation in human liver would be mainly catalyzed by UGT1A1. Interindividual differences in the troglitazone glucuronosyltransferase activity in S-9 samples from five human intestines was 8.2-fold. The troglitazone glucuronosyltransferase activity in human jejunum microsomes was strongly inhibited by emodin (IC50 = 15.6 µM), a typical substrate of UGT1A8 and UGT1A10, rather than by bilirubin (IC50 = 154.0 µM). Therefore, it is suggested that the troglitazone glucuronidation in human intestine might be mainly catalyzed by UGT1A8 and UGT1A10.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
P. J. Murphy
The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008
Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. Yamanaka, M. Nakajima, M. Katoh, and T. Yokoi
Glucuronidation of Thyroxine in Human Liver, Jejunum, and Kidney Microsomes
Drug Metab. Dispos., September 1, 2007; 35(9): 1642 - 1648.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Katoh, T. Matsui, and T. Yokoi
Glucuronidation of Antiallergic Drug, Tranilast: Identification of Human UDP-Glucuronosyltransferase Isoforms and Effect of Its Phase I Metabolite
Drug Metab. Dispos., April 1, 2007; 35(4): 583 - 589.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo Jr., et al.
N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
Drug Metab. Dispos., May 1, 2006; 34(5): 748 - 755.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Katoh, T. Matsui, H. Okumura, M. Nakajima, M. Nishimura, S. Naito, C. Tateno, K. Yoshizato, and T. Yokoi
EXPRESSION OF HUMAN PHASE II ENZYMES IN CHIMERIC MICE WITH HUMANIZED LIVER
Drug Metab. Dispos., September 1, 2005; 33(9): 1333 - 1340.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Di Marco, M. D'Antoni, S. Attaccalite, P. Carotenuto, and R. Laufer
DETERMINATION OF DRUG GLUCURONIDATION AND UDP-GLUCURONOSYLTRANSFERASE SELECTIVITY USING A 96-WELL RADIOMETRIC ASSAY
Drug Metab. Dispos., June 1, 2005; 33(6): 812 - 819.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
N. Kasai, T. Sakaki, R. Shinkyo, S.-i. Ikushiro, T. Iyanagi, M. Ohta, and K. Inouye
METABOLISM OF 26,26,26,27,27,27-F6-1{alpha},23S,25-TRIHYDROXYVITAMIN D3 BY HUMAN UDP-GLUCURONOSYLTRANSFERASE 1A3*
Drug Metab. Dispos., January 1, 2005; 33(1): 102 - 107.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. A. Gregory, R. H. Lewinsky, D. A. Gardner-Stephen, and P. I. Mackenzie
Coordinate Regulation of the Human UDP-Glucuronosyltransferase 1A8, 1A9, and 1A10 Genes by Hepatocyte Nuclear Factor 1{alpha} and the Caudal-Related Homeodomain Protein 2
Mol. Pharmacol., April 1, 2004; 65(4): 953 - 963.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
T. Nozawa, S. Sugiura, M. Nakajima, A. Goto, T. Yokoi, J.-I. Nezu, A. Tsuji, and I. Tamai
INVOLVEMENT OF ORGANIC ANION TRANSPORTING POLYPEPTIDES IN THE TRANSPORT OF TROGLITAZONE SULFATE: IMPLICATIONS FOR UNDERSTANDING TROGLITAZONE HEPATOTOXICITY
Drug Metab. Dispos., March 1, 2004; 32(3): 291 - 294.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Y. Watanabe, M. Nakajima, N. Ohashi, T. Kume, and T. Yokoi
Glucuronidation of Etoposide in Human Liver Microsomes Is Specifically Catalyzed by UDP-Glucuronosyltransferase 1A1
Drug Metab. Dispos., May 1, 2003; 31(5): 589 - 595.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. Barbier, L. Villeneuve, V. Bocher, C. Fontaine, I. P. Torra, C. Duhem, V. Kosykh, J.-C. Fruchart, C. Guillemette, and B. Staels
The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor alpha and gamma Target Gene
J. Biol. Chem., April 11, 2003; 278(16): 13975 - 13983.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Nakajima, E. Tanaka, J.-T. Kwon, and T. Yokoi
Characterization of Nicotine and Cotinine N-Glucuronidations in Human Liver Microsomes
Drug Metab. Dispos., December 1, 2002; 30(12): 1484 - 1490.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.